New Clinical Trial for Hidradenitis Suppurative (HS)


We are excited to announce a New Clinical Trial added to Menter Dermatology Research Institute for Hidradenitis Suppurativa (HS)! This is a great opportunity for patients with a chronic disease with limited treatment options.
hidradenitis suppurativa

If you or someone you know is suffering from HS, Call TODAY – 855.554.6374

note: Qualified study participants will receive study drug, related testing, and compensation for their time and travel.

Current HS Clinical Trial:

Clinical Trial Government Identifier #NCT03713619

Sponsor: Novartis

Genders eligible for study: Male/Female Ages eligible for study: 18 and older
NEW STUDY, NOW ENROLLING – HS (hidradenitis suppurativa) present for at least 1 year; at least 5 active lesions in two areas; no prior use of Cosentyx (secukinumab) allowed August 2019 – TBD